← Back to Search

Anticholinergic

Intranasal Scopolamine for Motion Sickness

Phase 2
Recruiting
Led By Scott J Wood, PhD
Research Sponsored by Repurposed Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the feasibility & efficacy of administering intranasal scopolamine gel to astronauts & ground-controls exposed to motion simulations to prevent/treat motion sickness. Participants complete short questionnaires & discuss countermeasures used & effectiveness.

Who is the study for?
This trial is for astronauts and test personnel who experience motion during their duties, like in simulations or parabolic flights. They must not have neurological disorders, narrow-angle glaucoma, urinary retention issues, or a recent positive COVID-19 test.
What is being tested?
The study tests an intranasal scopolamine gel (DPI-386) against other treatments like promethazine to prevent or treat motion sickness in spaceflight-related activities. Participants will use the medication in real operational settings and provide feedback.
What are the potential side effects?
Scopolamine may cause side effects such as dry mouth, dizziness, blurred vision, and drowsiness. It's important that participants don't have conditions that could be exacerbated by these effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Motion sickness (MS) symptoms using Pensacola Diagnostic Index (PDI) nausea scale.
Secondary study objectives
Drowsiness severity
Headache severity
Motion sickness impact on performance of functional tasks (from 0 = none to 4 = severe)
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: DPI-386 Nasal GelExperimental Treatment1 Intervention
DPI-386 Nasal Gel, 0.4 mg
Group II: ControlExperimental Treatment1 Intervention
Another form of preventative or treatment medication for motion sickness (e.g., promethazine or meclizine)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DPI-386 Nasal Gel
2021
Completed Phase 3
~750

Find a Location

Who is running the clinical trial?

Repurposed Therapeutics, Inc.Lead Sponsor
10 Previous Clinical Trials
1,689 Total Patients Enrolled
National Aeronautics and Space Administration (NASA)FED
30 Previous Clinical Trials
1,798 Total Patients Enrolled
Scott J Wood, PhDPrincipal InvestigatorNational Aeronautics and Space Administration (NASA)
1 Previous Clinical Trials
30 Total Patients Enrolled

Media Library

Intranasal Scopolamine (Anticholinergic) Clinical Trial Eligibility Overview. Trial Name: NCT05852730 — Phase 2
Space sickness Research Study Groups: Control, DPI-386 Nasal Gel
Space sickness Clinical Trial 2023: Intranasal Scopolamine Highlights & Side Effects. Trial Name: NCT05852730 — Phase 2
Intranasal Scopolamine (Anticholinergic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05852730 — Phase 2
~28 spots leftby Sep 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top